RhumbLine Advisers
ELTX icon

RhumbLine Advisers’s Elicio Therapeutics ELTX Stock Holding History

RhumbLine Advisers’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Buy
+6,681
New +$67.1K ﹤0.01% 3782
2022
Q2 		– Sell
-1,170
Closed -$25K – 3138
2022
Q1 		$25K Buy
1,170
+75
+7% +$1.69K ﹤0.01% 3000
2021
Q4 		$32K Hold
1,095
– – ﹤0.01% 2995
2021
Q3 		$107K Buy
+1,095
New +$118K ﹤0.01% 2987

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

RhumbLine Advisers's ELTX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 6,681 shares worth $26.1K. The stake represents ﹤0.01% of the portfolio and ranks #3782 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ELTX as recently as Q1 2022.

RhumbLine Advisers first reported a position in ELTX in Q3 2021 and has held it in 4 quarters since. The position peaked at $107K in Q3 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • RhumbLine Advisers held 6,681 shares of Elicio Therapeutics worth $26.1K as of Q2 2026.
  • Elicio Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3782 holding.
  • RhumbLine Advisers first reported a position in Elicio Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • RhumbLine Advisers's Elicio Therapeutics position peaked at $107K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.